Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PHARNEXT

Home Clinical Trial Sponsors and OrganizationsPHARNEXT

PHARNEXT

14 RUE DE LA REPUBLIQUE, Suresnes, Île-de-France, France

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

9

8 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

7

77.8%

Phase 3

1

11.1%

Trial Status Distribution

Active, not recruiting

8

88.9%

Completed

1

11.1%

Clinical Trials

Trials sponsored by this organization (9)

An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Active, not recruiting

Apr 2017300 participants

An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Active, not recruiting

Jan 2017290 participants

An International, multi-center, 9-month FOLLOW-UP extension study to study the long term safety of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Active, not recruiting

Jan 2017300 participants

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Active, not recruiting

Dec 2015323 participants

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Active, not recruiting

Oct 2015323 participants

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Active, not recruiting

Sep 2015300 participants

International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Active, not recruiting

Jul 2015323 participants

A Phase II, Randomised, Placebo-Controlled Trial of the Safety, Efficacy, Pharmacodynamics of PTX3003 in Patients with Charcot-Marie-Tooth Disease Type 1A - non applicable

Active, not recruiting

Oct 201080 participants

Page 1 of 2

Approvals

No approval data available

News

Pharnext's CMT1A Drug PXT3003 Fails to Meet Primary Endpoint in Phase 3 PREMIER Trial

- French biotech Pharnext's lead drug PXT3003 for Charcot-Marie-Tooth disease type 1A failed to demonstrate superiority over placebo in Phase 3 PREMIER trial due to unexpected placebo response. - Despite the setback, Pharnext remains optimistic, citing 10 years of accumulated data and an ongoing Phase 3 trial with Chinese partner Tasly that could support regulatory submission. - PXT3003, a combination of baclofen, naltrexone, and sorbitol, maintained its favorable safety profile and showed no disease deterioration in treated patients during the study period.

On this page

Overview
Clinical Trials9
Approvals
News1

Back to Organizations